Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Zhenyun Guo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5058500778. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-025-08135-5↗
  2. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  3. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05939-1↗
  4. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Co-author DOI 10.3389/fonc.2022.962204↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 4 shared papers, 2022–2026 · strength 0.87
  2. Chengjie Lin · 4 shared papers, 2022–2026 · strength 0.87
  3. Shihui Lai · 3 shared papers, 2023–2026 · strength 0.70
  4. Yue Huang · 3 shared papers, 2022–2023 · strength 0.55
  5. Xiang Zhang · 3 shared papers, 2022–2023 · strength 0.55
  6. Yan Wang · 1 shared paper, 2023 · strength 0.19
  7. Yun Zhong · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.